Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor antigen protein and tumor vaccine

A tumor antigen and tumor vaccine technology, which is applied in the direction of tumor-specific antigen, tumor rejection antigen precursor, anti-tumor drugs, etc., can solve the problems of poor therapeutic effect and poor specificity of peptide vaccines, and achieve good therapeutic effect and good therapeutic effect. Safety and efficacy, effect of increasing action time

Inactive Publication Date: 2017-02-22
蔡炯
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In view of the poor specificity of the antigen peptide based on the VNTR of MUC1 and the poor therapeutic effect of the peptide vaccine in the prior art, the present invention provides a tumor antigen peptide on the one hand, and a tumor antigen peptide prepared from the tumor antigen peptide on the other hand. tumor vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor antigen protein and tumor vaccine
  • Tumor antigen protein and tumor vaccine
  • Tumor antigen protein and tumor vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1 prepares MCMVax vaccine

[0041] 1. MUC1-Xex gene design and synthesis

[0042] The MUC1-Xex coding gene was designed using DNA design software, the coding gene was codon optimized, and an NdeI endonuclease site was introduced at its 5' end, and an NcoI endonuclease site was introduced at the 3' end, as shown in SEQ ID NO:4 , The synthetic gene was cloned into the pUC57 vector, ampicillin resistance.

[0043] 2. Enzyme digestion and sequencing identification of genes

[0044] After gene synthesis, double digestion was performed with NdeI and NcoI endonucleases, ligated into the pMAL-p5X plasmid that had undergone the same digestion, ligated with DNA ligase, and transformed into competent DH5α bacteria. Screen on agar culture plates containing ampicillin (AMP), select single clones and culture them in LB-AMP medium (i.e. LB medium containing AMP), extract plasmids and identify them, and then send them to Beijing Tianyi Huiyuan Biotechnology Co., Ltd. Co.,...

Embodiment 2

[0053] Example 2 The inhibitory effect of MCMVax on melanoma

[0054] Fifteen male C57BL / 6J mice aged 6-8 weeks were divided into three groups: control group, MNRVax treatment group and MCMVax treatment group, with 5 mice in each group, and B16-Muc1 melanoma cells were inoculated subcutaneously in the right armpit of each mouse for 2.8 ×10 6 One, the tumor was visible after 5 days.

[0055] In the control group, 100 μL of normal saline was injected into the hind leg muscles of each mouse, twice a week, for a total of 4 injections;

[0056] In the MNRVax treatment group, 50 μg of MNRVax was injected into the hind leg muscle of each mouse, twice a week, for a total of 4 injections;

[0057] In the MCMVax treatment group, 50 μg of MCMVax was injected into the hind leg muscle of each mouse, twice a week, for a total of 4 times.

[0058] The results showed that compared with the mice in the control group, the tumors of the mice in the MCMVax treatment group were significantly re...

Embodiment 3

[0062] Example 3 The inhibitory effect of MCMVax combined with MNRVax on melanoma

[0063] Twenty-four male C57BL / 6J mice aged 6-8 weeks were divided into four groups: control group, MNRVax treatment group, MCMVax treatment group, MNRVax and MCMVax combined treatment group, 6 mice in each group, and inoculated subcutaneously in the right armpit of each mouse B16-Muc1 melanoma cells 2.4×10 6 One, the tumor was visible after 9 days.

[0064] The formulations were injected into the hind leg muscles of the mice, 3 times a week, 3 times in total. Among them, the control group was injected with 200 μL of normal saline each time; the MNRVax treatment group was injected with 50 μg MNRVax each time; the MCM Vax treatment group was injected with 50 μg MCMVax each time; the combined treatment group was injected with 50 μg MNRVax plus 50 μg MCMVax each time.

[0065] The results showed that compared with the mice in the control group, the tumors of the mice in the MCMVax treatment group w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a tumor antigen protein and a tumor vaccine. The tumor antigen protein comprises a human tumor cell membrane MUC1-Xex peptide fragment, and an amino acid sequence of the MUC1-Xex peptide fragment is as shown in SEQ ID No: 1. The tumor vaccine contains the tumor antigen protein. The tumor antigen protein selects MUC1-Xex peptide fragment with an MUC1 target point as an antigen, thus having very good safety; more preferentially, an adjuvant immune stimulating protein is directly coupled with the MUC1-Xex peptide fragment by means of gene fusion recombinant expression, so that the immunogenicity is improved. The tumor vaccine selects a clinical commonly used aluminum adjuvant as an auxiliary material, so that the action time of the vaccine is prolonged. Finally, animal experiments prove that after being intramuscularly injected, the obtained tumor vaccine has good safety and effectiveness. The tumor vaccine has a good treatment effect on malignant tumors, especially for lung cancer, melanoma and colon cancer.

Description

technical field [0001] The invention relates to the technical field of tumor immunotherapy, in particular to a tumor antigen protein and its related tumor vaccine. Background technique [0002] At present, there are about 2.5 million new cancer patients in my country every year, and about 1.4 million people die from cancer. In the future, air and water pollution and environmental damage may further increase the incidence and mortality of cancer. The study of cancer therapeutic drugs is a research hotspot in the world today. In addition to surgery, chemotherapy, and radiotherapy for cancer treatment, biological immunotherapy has developed rapidly in recent years, and cell therapy, antibody therapy, and vaccine therapy have formed a three-pronged trend, and there is a great possibility of eradicating cancer. [0003] Melanoma is a cancer of melanocytes that develops primarily in the skin and occasionally in the mouth, small intestine, and eyes. In women it occurs most often...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47C07K19/00C12N15/12C12N15/62C12N15/70A61K39/00A61P35/00
CPCC07K14/4748A61K39/0011A61K2039/55505C07K2319/24C12N15/70
Inventor 蔡炯
Owner 蔡炯
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com